You are viewing the site in preview mode

Skip to main content


We're creating a new version of this page. See preview

  • Oral presentation
  • Open Access

The impact of nonalcoholic fatty liver disease on chronic viral hepatitis – progression to cirrhosis

  • 1Email author,
  • 2,
  • 2,
  • 1,
  • 2 and
  • 1
BMC Infectious Diseases201313 (Suppl 1) :O27

  • Published:


  • Obesity
  • Liver Disease
  • Metabolic Syndrome
  • Alcohol Consumption
  • Independent Risk Factor


Nonalcoholic fatty liver disease (NAFDL) is the hepatic manifestation of the metabolic syndrome (MS) and it is associated with obesity, diabetes mellitus and dyslipidemia. We evaluated the impact of NAFLD on chronic viral hepatitis (HBV and HCV) and the progression to cirrhosis for these patients.


Between April 2011 and March 2013, 210 consecutive patients with chronic viral hepatitis were submitted. Patients with excessive alcohol consumption (above 20 g/day for males, 10 g/day for females) have been excluded. The steatosis, necroinflammatory activity and fibrosis were estimated using FibroMax (non-invasive liver tests). The serological and virological tests established the diagnosis of chronic viral hepatitis. We divided the patients into 2 groups: patients without steatosis (n=80) and with steatosis (n=130).


Statistical analysis pointed out the prevalence of female (62.7%); average age 42.3±10.72 years. The presence of steatosis (≥S1 – SteatoTest) was significantly correlated with: female gender (p=0.028), older age (p=0.003) and the degree of hepatic fibrosis (≥F3 – FibroTest, p=0.001).


The prevalence of steatosis in chronic viral hepatitis was 61.9%. We observed a positive correlation of steatosis with age, female sex and the fibrosis stage. Steatosis was an independent risk factor for progression of the liver disease.

Authors’ Affiliations

National Institute for Infectious Diseases “Prof. Dr. Matei Balş”, Bucharest, Romania
University Emergency Hospital, Bucharest, Romania


© Olariu et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.